Replies to post #191871 on Biotech Values

[DewDiligence]

JNP—The in-licensed IVR can disseminate glycosylated proteins (not just peptides), according to JNP’s Marcum webcast, so that might be the goal.

Does “NET” in your post mean natural estrogen therapy?

[DewDiligence]

JNP enrolls first patient in phase-2 trial of COL-1077:

http://finance.yahoo.com/news/juniper-pharmaceuticals-announces-first-patient-110000974.html

[DewDiligence]

JNP appoints James Geraghty as Chairman:

http://finance.yahoo.com/news/juniper-pharmaceuticals-announces-board-changes-205800937.html

Geraghty is Chairman of two other biotech companies: rEvo Biologics (the successor company to GTCB) and IDRA. This appointment makes me somewhat less favorably inclined toward JNP.

[DewDiligence]

(JNP)—Ferring Pharma acquires progesterone vaginal ring from TEVA for undisclosed price:

http://finance.yahoo.com/news/ferring-pharmaceuticals-acquires-global-rights-120000940.html

[DewDiligence]

JNP—Robert Langer will be among the speakers at JNP’s Investor Day webcast tomorrow:

http://finance.yahoo.com/news/juniper-pharmaceuticals-announces-speakers-november-130000616.html

[DewDiligence]

JNP discloses three pipeline applications of intra-vaginal ring:

http://finance.yahoo.com/news/juniper-pharmaceuticals-adds-three-products-142000974.html

• JNP-0101, an oxybutynin IVR for the treatment of overactive bladder;

• JNP-0201, a combination IVR delivering estrogen and progesterone hormone replacement therapy (HRT); and,

• JNP-0301, a progesterone IVR for the prevention of preterm birth.

More details in the PR.

Comments?